Figure 2. PD-L1 expression and CD8⁺ TILs before and after developing acquired resistance to EGFR-TKI therapy among patients with available paired tissues (n = 47).

(A) Change of TPS for PD-L1in EGFR mutant NSCLC before EGFR-TKI and after developing resistance to EGFR-TKI among the patient with available paired biopsies (n = 47). (B) Change of TPS for PD-L1 according to pre-TKI TPS for PD-L1 among the patient with available paired biopsies (n = 47). ^*High post -TKI TPS for PD-L1 and post-TKI low CD8⁺ TILs score patients (n = 8). (C) Change of CD8⁺ TILs score in EGFR mutant NSCLC pre-TKI and post-TKI between high and low post-TKI TPS of PDL-1 group among the patient with available paired biopsies (n = 47).